Cytomegalovirus quantification: Where to next in optimising patient management?

Journal of Clinical Virology

Volumn 51, Issue 4, 2011, Pages 223-228

  Atkinson, Claire ^a   Emery, Vincent C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Antiviral therapy; HCMV disease; Pathogenesis; PCR

Indexed keywords

ACICLOVIR; CIDOFOVIR; CYTOMEGALOVIRUS ANTIGEN PP65; CYTOMEGALOVIRUS VACCINE; FOSCARNET; GANCICLOVIR; MATRIX PROTEIN; PROTEIN P72; VALACICLOVIR; VALGANCICLOVIR; VIRUS DNA;

AIDS PATIENT; ANTIGEN DETECTION; ANTIVIRAL RESISTANCE; ANTIVIRAL THERAPY; CROHN DISEASE; CYTOMEGALOVIRUS INFECTION; DNA DETERMINATION; DNA RNA HYBRIDIZATION; DRUG BIOAVAILABILITY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CYTOMEGALOVIRUS; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INFECTION PREVENTION; INFECTION RISK; INTERMETHOD COMPARISON; LEUKOCYTE; NONHUMAN; ORGAN TRANSPLANTATION; PATIENT CARE; PERCEPTION DEAFNESS; PERSONAL EXPERIENCE; PERSONALIZED MEDICINE; PREDICTIVE VALUE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVIEW; SENSITIVITY AND SPECIFICITY; STEM CELL TRANSPLANTATION; TREATMENT RESPONSE; TURNAROUND TIME; ULCERATIVE COLITIS; VIRUS GENOME; VIRUS LOAD; VIRUS REPLICATION;

EID: 79960042509     PISSN: 13866532     EISSN: 18735967     Source Type: Journal    
DOI: 10.1016/j.jcv.2011.04.007     Document Type: Review

References (64)

1. Griffiths P.D., Emery V.C., Milne R.C. Cytomegalovirus. Clinical virology 2009, 475-506. ASM Press. 3rd ed. D. Douglas, Richmand, R.J. Whitley (Eds.).
2. Ljungman P., Griffiths P., Paya C. Definitions of cytomegalovirus infection and disease in transplant recipients. Clin Infect Dis 2002, 34(8):1094-1097.
3. Sylwester A.W., Mitchell B.L., Edgar J.B., Taormina C., Pelte C., Ruchti F., et al. Broadly targeted human cytomegalovirus-specific CD4+ and CD8+ T cells dominate the memory compartments of exposed subjects. J Exp Med 2005, 202(5):673-685.
4. Fishman J.A., Rubin R.H. Infection in organ-transplant recipients. N Engl J Med 1998, 338(24):1741-1751.
5. Nebbia G., Emery V.C. Assessing the full impact of the indirect effects of cytomegalovirus following solid organ transplantation. Trends Transplant 2009, 3:41-52.
6. Soderberg-Naucler C. HCMV microinfections in inflammatory diseases and cancer. J Clin Virol 2008, 41(3):218-223.
7. Pass R.F. Development and evidence for efficacy of CMV glycoprotein B vaccine with MF59 adjuvant. J Clin Virol 2009, 46(Suppl. l4):S73-S76.
8. Pass R.F., Zhang C., Evans A., Simpson T., Andrews W., Huang M.L., et al. Vaccine prevention of maternal cytomegalovirus infection. N Engl J Med 2009, 360(12):1191-1199.
9. Smith M.G. Propagation in tissue cultures of a cytopathogenic virus from human salivary gland virus (SGV) disease. Proc Soc Exp Biol Med 1956, 92:418-424.
10. Rowe W.P., Hartley J.W., Waterman S., Turner H.C., Huebner R.J. Cytopathogenic agent resembling human salivary gland virus recovered from tissue cultures of human adenoids. Proc Soc Exp Biol Med 1956, 92(2):418-424.
11. Craig J.M., Macauley J.C., Weller T.H., Wirth P. Isolation of intranuclear inclusion producing agents from infants with illnesses resembling cytomegalic inclusion disease. Proc Soc Exp Biol Med 1957, 94(1):4-12.
12. Stagno S., Reynolds D.W., Tsiantos A., Fuccillo D.A., Long W., Alford C.A. Comparative serial virologic and serologic studies of symptomatic and subclinical congenitally and natally acquired cytomegalovirus infections. J Infect Dis 1975, 132(5):568-577.
13. Gleaves C.A., Smith T.F., Shuster E.A., Pearson G.R. Rapid detection of cytomegalovirus in MRC-5 cells inoculated with urine specimens by using low-speed centrifugation and monoclonal antibody to an early antigen. J Clin Microbiol 1984, 19(6):917-919.
14. Griffiths P.D., Panjwani D.D., Stirk P.R., Ball M.G., Ganczakowski M., Blacklock H.A., et al. Rapid diagnosis of cytomegalovirus infection in immunocompromised patients by detection of early antigen fluorescent foci. Lancet 1984, 2(8414):1242-1245.
15. Gerna G., Revello M.G., Percivalle E., Zavattoni M., Parea M., Battaglia M. Quantification of human cytomegalovirus viremia by using monoclonal antibodies to different viral proteins. J Clin Microbiol 1990, 28(12):2681-2688.
16. van den Berg A.P., van der B.W., van Son W.J., Anema J., van der G.M., Schirm J., et al. Cytomegalovirus antigenemia as a useful marker of symptomatic cytomegalovirus infection after renal transplantation-a report of 130 consecutive patients. Transplantation 1989, 48(6):991-995.
17. Gerna G., Revello M.G., Percivalle E., Morini F. Comparison of different immunostaining techniques and monoclonal antibodies to the lower matrix phosphoprotein (pp65) for optimal quantitation of human cytomegalovirus antigenemia. J Clin Microbiol 1992, 30(5):1232-1237.
18. Meyers J.D., Ljungman P., Fisher L.D. Cytomegalovirus excretion as a predictor of cytomegalovirus disease after marrow transplantation: importance of cytomegalovirus viremia. J Infect Dis 1990, 162(2):373-380.
19. Murray B.M., Amsterdam D., Gray V., Myers J., Gerbasi J., Venuto R. Monitoring and diagnosis of cytomegalovirus infection in renal transplantation. J Am Soc Nephrol 1997, 8(9):1448-1457.
20. van den Berg A.P., Klompmaker I.J., Haagsma E.B., Scholten-Sampson A., Bijleveld C.M., Schirm J., et al. Antigenemia in the diagnosis and monitoring of active cytomegalovirus infection after liver transplantation. J Infect Dis 1991, 164(2):265-270.
21. Dodt K.K., Jacobsen P.H., Hofmann B., Meyer C., Kolmos H.J., Skinhoj P., et al. Development of cytomegalovirus (CMV) disease may be predicted in HIV-infected patients by CMV polymerase chain reaction and the antigenemia test. AIDS 1997, 11(3):F21-F28.
22. Sandin R.L., Rodriguez E.R., Rosenberg E., Porter-Jordan K., Caparas M., Nasim S., et al. Comparison of sensitivity for human cytomegalovirus of the polymerase chain reaction, traditional tube culture and shell vial assay by sequential dilutions of infected cell lines. J Virol Methods 1991, 32(2-3):181-191.
23. Kidd I.M., Fox J.C., Pillay D., Charman H., Griffiths P.D., Emery V.C. Provision of prognostic information in immunocompromised patients by routine application of the polymerase chain reaction for cytomegalovirus. Transplantation 1993, 56(4):867-871.
24. Gor D., Sabin C., Prentice H.G., Vyas N., Man S., Griffiths P.D., et al. Longitudinal fluctuations in cytomegalovirus load in bone marrow transplant patients: relationship between peak virus load, donor/recipient serostatus, acute GVHD and CMV disease. Bone Marrow Transplant 1998, 21(6):597-605.
25. Fox J.C., Kidd I.M., Griffiths P.D., Sweny P., Emery V.C. Longitudinal analysis of cytomegalovirus load in renal transplant recipients using a quantitative polymerase chain reaction: correlation with disease. J Gen Virol 1995, 76(Pt 2):309-319.
26. Sia I.G., Wilson J.A., Espy M.J., Paya C.V., Smith T.F. Evaluation of the COBAS AMPLICOR CMV MONITOR test for detection of viral DNA in specimens taken from patients after liver transplantation. J Clin Microbiol 2000, 38(2):600-606.
27. Emery V.C., Cope A.V., Bowen E.F., Gor D., Griffiths P.D. The dynamics of human cytomegalovirus replication in vivo. J Exp Med 1999, 190(2):177-182.
28. Emery V.C., Sabin C.A., Cope A.V., Gor D., Hassan-Walker A.F., Griffiths P.D. Application of viral-load kinetics to identify patients who develop cytomegalovirus disease after transplantation. Lancet 2000, 355(9220):2032-2036.
29. Mazzulli T., Drew L.W., Yen-Lieberman B., Jekic-McMullen D., Kohn D.J., Isada C., et al. Multicenter comparison of the digene hybrid capture CMV DNA assay (version 2.0), the pp65 antigenemia assay, and cell culture for detection of cytomegalovirus viremia. J Clin Microbiol 1999, 37(4):958-963.
30. Compton J. Nucleic acid sequence-based amplification. Nature 1991, 350(6313):91-92.
31. Mengoli C., Cusinato R., Biasolo M.A., Cesaro S., Parolin C., Palu G. Assessment of CMV load in solid organ transplant recipients by pp65 antigenemia and real-time quantitative DNA PCR assay: correlation with pp67 RNA detection. J Med Virol 2004, 74(1):78-84.
32. Caliendo A.M., Yen-Lieberman B., Baptista J., Andersen J., Crumpacker C., Schuurman R., et al. Comparison of molecular tests for detection and quantification of cell-associated cytomegalovirus DNA. J Clin Microbiol 2003, 41(8):3509-3513.
33. Deback C., Fillet A.M., Dhedin N., Barrou B., Varnous S., Najioullah F., et al. Monitoring of human cytomegalovirus infection in immunosuppressed patients using real-time PCR on whole blood. J Clin Virol 2007, 40(3):173-179.
34. Caliendo A.M., Shahbazian M.D., Schaper C., Ingersoll J., Abdul-Ali D., Boonyaratanakornkit J., et al. A commutable cytomegalovirus calibrator is required to improve the agreement of viral load values between laboratories. Clin Chem 2009, 55(9):1701-1710.
35. Pang X.L., Fox J.D., Fenton J.M., Miller G.G., Caliendo A.M., Preiksaitis J.K. Interlaboratory comparison of cytomegalovirus viral load assays. Am J Transplant 2009, 9(2):258-268.
36. Lilleri D., Lazzarotto T., Ghisetti V., Ravanini P., Capobianchi M.R., Baldanti F., et al. Multicenter quality control study for human cytomegalovirus DNAemia quantification. New Microbiol 2009, 32(3):245-253.
37. Emery V.C., Griffiths P.D. Prediction of cytomegalovirus load and resistance patterns after antiviral chemotherapy. Proc Natl Acad Sci USA 2000, 97(14):8039-8044.
38. Levitsky J., Freifeld A.G., Puumala S., Bargenquast K., Hardiman P., Gebhart C., et al. Cytomegalovirus viremia in solid organ transplantation: does the initial viral load correlate with risk factors and outcomes?. Clin Transplant 2008, 22(2):222-228.
39. Bowen E.F., Sabin C.A., Wilson P., Griffiths P.D., Davey C.C., Johnson M.A., et al. Cytomegalovirus (CMV) viraemia detected by polymerase chain reaction identifies a group of HIV-positive patients at high risk of CMV disease. AIDS 1997, 11(7):889-893.
40. Spector S.A., Hsia K., Crager M., Pilcher M., Cabral S., Stempien M.J. Cytomegalovirus (CMV) DNA load is an independent predictor of CMV disease and survival in advanced AIDS. J Virol 1999, 73(8):7027-7030.
41. Cope A.V., Sweny P., Sabin C., Rees L., Griffiths P.D., Emery V.C. Quantity of cytomegalovirus viruria is a major risk factor for cytomegalovirus disease after renal transplantation. J Med Virol 1997, 52(2):200-205.
42. Cope A.V., Sabin C., Burroughs A., Rolles K., Griffiths P.D., Emery V.C. Interrelationships among quantity of human cytomegalovirus (HCMV) DNA in blood, donor-recipient serostatus, and administration of methylprednisolone as risk factors for HCMV disease following liver transplantation. J Infect Dis 1997, 176(6):1484-1490.
43. Sanghavi S.K., bu-Elmagd K., Keightley M.C., St G.K., Lewandowski K., Boes S.S., et al. Relationship of cytomegalovirus load assessed by real-time PCR to pp65 antigenemia in organ transplant recipients. J Clin Virol 2008, 42(4):335-342.
44. Lazzarotto T., Varani S., Guerra B., Nicolosi A., Lanari M., Landini M.P. Prenatal indicators of congenital cytomegalovirus infection. J Pediatr 2000, 137(1):90-95.
45. Guerra B., Lazzarotto T., Quarta S., Lanari M., Bovicelli L., Nicolosi A., et al. Prenatal diagnosis of symptomatic congenital cytomegalovirus infection. Am J Obstet Gynecol 2000, 183(2):476-482.
46. Revello M.G., Zavattoni M., Furione M., Baldanti F., Gerna G. Quantification of human cytomegalovirus DNA in amniotic fluid of mothers of congenitally infected fetuses. J Clin Microbiol 1999, 37(10):3350-3352.
47. Ross S.A., Novak Z., Fowler K.B., Arora N., Britt W.J., Boppana S.B. Cytomegalovirus blood viral load and hearing loss in young children with congenital infection. Pediatr Infect Dis J 2009, 28(7):588-592.
48. Amir J., Wolf D.G., Levy I. Treatment of symptomatic congenital cytomegalovirus infection with intravenous ganciclovir followed by long-term oral valganciclovir. Eur J Pediatr 2010, 169(9):1061-1067.
49. Walter S., Atkinson C., Sharland M., Rice P., Raglan E., Emery V.C., et al. Congenital cytomegalovirus: association between dried blood spot viral load and hearing loss. Arch Dis Child Fetal Neonat Ed 2008, 93(4):F280-F285.
50. Mattes F.M., McLaughlin J.E., Emery V.C., Clark D.A., Griffiths P.D. Histopathological detection of owl's eye inclusions is still specific for cytomegalovirus in the era of human herpesviruses 6 and 7. J Clin Pathol 2000, 53(8):612-614.
51. Ganzenmueller T., Henke-Gendo C., Schlue J., Wedemeyer J., Huebner S., Heim A. Quantification of cytomegalovirus DNA levels in intestinal biopsies as a diagnostic tool for CMV intestinal disease. J Clin Virol 2009, 46(3):254-258.
52. Li Y.T., Emery V.C., Surah S., Jarmulowicz M., Sweny P., Kidd I.M., et al. Extensive human cytomegalovirus (HCMV) genomic DNA in the renal tubular epithelium early after renal transplantation: relationship with HCMV DNAemia and long-term graft function. J Med Virol 2010, 82(1):85-93.
53. Razonable R.R. Strategies for managing cytomegalovirus in transplant recipients. Expert Opin Pharmacother 2010, 11(12):1983-1997.
54. Mattes F.M., Hainsworth E.G., Hassan-Walker A.F., Burroughs A.K., Sweny P., Griffiths P.D., et al. Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis 2005, 191(1):89-92.
55. Gerna G., Baldanti F., Torsellini M., Minoli L., Vigano M., Oggionnis T., et al. Evaluation of cytomegalovirus DNAaemia versus pp65-antigenaemia cutoff for guiding preemptive therapy in transplant recipients: a randomized study. Antivir Ther 2007, 12(1):63-72.
56. Gerna G., Lilleri D., Rognoni V., Agozzino M., Meloni F., Oggionni T., et al. Preemptive therapy for systemic and pulmonary human cytomegalovirus infection in lung transplant recipients. Am J Transplant 2009, 9(5):1142-1150.
57. Gerna G., Lilleri D., Caldera D., Furione M., Zenone B.L., Alessandrino E.P. Validation of a DNAemia cutoff for preemptive therapy of cytomegalovirus infection in adult hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2008, 41(10):873-879.
58. Paya C., Humar A., Dominguez E., Washburn K., Blumberg E., Alexander B., et al. Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2004, 4(4):611-620.
59. Humar A., Lebranchu Y., Vincenti F., Blumberg E.A., Punch J.D., Limaye A.P., et al. The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients. Am J Transplant 2010, 10(5):1228-1237.
60. Asberg A., Humar A., Rollag H., Jardine A.G., Mouas H., Pescovitz M.D., et al. Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 2007, 7(9):2106-2113.
61. Buyck H.C., Griffiths P.D., Emery V.C. Human cytomegalovirus (HCMV) replication kinetics in stem cell transplant recipients following anti-HCMV therapy. J Clin Virol 2010, 49:32-36.
62. Kotton C.N., Kumar D., Caliendo A.M., Asberg A., Chou S., Snydman D.R., et al. International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 2010, 89(7):779-795.
63. Torre-Cisneros J., Caston-Osorio J.J., Martin C., Rivero A., Doblas A., Rojas R., et al. Impact of initial cytomegalovirus load on efficacy of preemptive therapy with ganciclovir in allogenic stem cell transplant recipients. Enferm Infecc Microbiol Clin 2010, 28:6-12.
64. Asberg A., Humar A., Jardine A.G., Rollag H., Pescovitz M.D., Mouas H., et al. Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 2009, 9(May (5)):1205-1213.